Immuno-Oncology (IO), Focal radiation, KPC mice, ADME/TOX services

Our Research Services

In vitro Studies

L2P Research® offers a wide range of in vitro studies specifically developed to serve our customers. These services sometimes provide a frame work to design in vivo efficacy studies. We are fully GLP compliant facility that operates under strict Internal SOPs and regulatory guidelines. Our in vitro services including: LC/MS Method Development and Validation (Bi...

Spontaneous Tumor Models

Spontaneous mouse models develop tumors under the influence of genetic modification that imitates natural disease condition in humans. Spontaneous tumor models provide most clinically relevant tumor microenvironment to study immunotherapeutic mechanism and strategies. L2P Research® offers spontaneous tumor models specific to Pancreas, prostate, lung, mammary Tumors, hea...

CD34+ engraftment

Immunodeficient mice engrafted with functional human cells and tissues have become increasingly important as pre-clinical animal models for the study of human diseases. L2P Research® offers CD34+ hematopoietic stem cell-engraftment service, these mice can develop multi-lineage human immune cells. < We Perform In-House verification by FACS to assess Engraftment > W...

Focal Radiation Studies

Focal radiation therapy delivers very precise and intense doses of radiation, typically in 1 to 5 total treatments. Studies combining Focal radiation with Antibody or chemo therapies have been gaining tremendous value to treat cancers. L2P Research® offers advanced stereotactic body radiation therapy (SBRT), also known as stereotactic ablative body radiotherapy (S...

Immuno-Oncology

Utilizing the strength of our own Immune system to fight cancers is proving to be very successful approach. Immuno-oncology (I/O) is emerging as one of the key areas in oncology drug discovery and development. L2P Research® offers more than 30 syngeneic cancer models to be used in immune competent mice. We have fully validated tumor lines ready to be implanted for your...

Tumor Studies

L2P Research has over 200 Tumor Cell lines available to use in Immune competent and immuno compromised mice. All our Cell line stocks are obtained from authentic sources and characterized in animal models. Our Tumor inoculation techniques offer lowest level of variability between animal to animal within the cohort. Our scientists meticulously perform the procedures to avoi...

366

Projects Done

55+

Happy Clients

12+

Experts

6+

Years of Experience

Our Research Quality

We Employ the Latest Research Technologies & Methods

L2P Research Labs takes pride of employing highly qualified scientists with several years of research experience. Our Research facilities are GLP compliant with robust quality assurance program in place. We equipped our Labs with state-of-the-art instruments to handle your IND enabling studies. We are committed to deliver high quality data that will further strengthen your research.

More Details

Latest News

L2P Research Labs Awarded NIH SBIR Grant for Arthritis, Musculoskeletal and Skin Diseases Research

Oct 27, 2023

This grant will explore a cell therapy approach for the treatment of osteoarthritis via delivery of human mesenchymal stem cells (MSC) and adipose-derived stem cells (ASC) in the form of three-dimensional hydrogels. L2P Labs will aim to combine the use of hydrogel, stem cells, and ultrasound therapy to develop a new treatment for osteoarthritis. These approaches have shown promise a...

Aug 24, 2022

News LinkAugust 19, 2022 11:22 AM Eastern Daylight Time ANNVILLE, Pa.--(BUSINESS WIRE)--L2P Research Labs, a leading preclinical CRO, today announced its annual research accomplishments. Dr. Suresh Anaganti, Chief Executive Officer of L2P Research Labs, shared contribution to preclinical data published in Cell Reports. Link: https://www.cell.com/cell-reports/pdf/S2211-1247(...

Feb 28, 2020

L2P Research LLC, a leading preclinical CRO, today announced that it had completed its acquisition of METIS Research Laboratories headquartered in Ronkonkoma, New York. The Acquisition adds to L2P’s network 5,000 square-foot GLP compliant facility which is focused on providing Radiobinding assays, preclinical toxicology and whole body autoradiograph (QWBA) for innovators of adv...

Jan 23, 2020

L2P Research, LLC and Transcell Oncologics, LLC have entered into a partnership with the purpose of marketing and the distribution of Transcell Oncologics, LLC Trans HSC (CD34+), Trans-HSC (PBMC) product line and L2P Research’s humanized mouse models. L2P Research, LLC is a Pennsylvania based Research organization founded with a vision to provide integrated R&a...

Mar 07, 2018

We are pleased to announce, the research project contracted by Rgenix Inc., has been published in “Cell ”. As a Contract research Organization (CRO) specialized in Oncology animal models, we are pleased to have this opportunity to work for Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer...

Feb 25, 2018

We are pleased to announce a novel technique to generate orthotopic Renal carcinoma in small animal model.We successfully used this technique to transplant renal carcinoma cells in to the kidney.This model can be used to perform efficacy and metastatic studies. L2P Research LLC, headquartered in Stony Brook, NY, is a USA-based firm that provides integrated R&D support in all the...

Feb 01, 2018

One of the major challenges in orthopedics is to develop implants that overcome currentpostoperative problems such as osteointegration, proper load bearing, and stress shielding. Current implant techniques such as allografts or endoprostheses never reach full bone integration, and the risk of fracture dueto stress shielding is a major concern. To overcome this, a novel technique of r...

May 18, 2017

We are pleased to announce that it received funding under the Applied Research and Development (ARAD) program. The funding approval is our first corporate sponsored research and testing agreement with Center for Biotechnology (CFB), L2P continues to build the momentum for the aggressive growth L2P is experiencing. Separately, this year, L2P closed research agreements for pr...

Mar 23, 2015

Governor Andrew M. Cuomo today announced that 10 more businesses plan to expand in or locate to New York State as a result of START-UP NY. These companies join the more than 80 companies already participating in the innovative Governor Andrew M. Cuomo today announced that 10 more businesses plan to expand in or locate to New York State as a result of START-UP NY. These compan...

We would love to hear from you

Feel free and share with us. We will get back to you.

We are just minutes from the heart of the New York Academic and Biotechnology Communities

GLP compliant and AAALAC approved research facilities

RADIATION RESEARCH

Featured Services